{"id":67004,"date":"2026-06-01T20:27:05","date_gmt":"2026-06-01T12:27:05","guid":{"rendered":"https:\/\/flcube.com\/?p=67004"},"modified":"2026-06-01T20:27:06","modified_gmt":"2026-06-01T12:27:06","slug":"d3-bios-next-gen-kras-g12c-inhibitor-elisrasib-shows-81-response-rate-in-first-line-nsclc-at-asco-2026","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=67004","title":{"rendered":"D3 Bio&#8217;s Next-Gen KRAS G12C Inhibitor Elisrasib Shows 81% Response Rate in First-Line NSCLC at ASCO 2026"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>D3 Bio<\/strong>, a China-based biotechnology company, presented <strong>updated Phase I\/II clinical data<\/strong> for <strong>elisrasib (D3S-001)<\/strong>, its <strong>next-generation KRAS G12C inhibitor<\/strong>, at the <strong>2026 American Society of Clinical Oncology (ASCO) Annual Meeting<\/strong>. The study evaluated elisrasib as <strong>monotherapy and in combination with pembrolizumab<\/strong> in patients with <strong>KRAS G12C-mutant (G12Cmut) non-small cell lung cancer (NSCLC)<\/strong>, with the <strong>first-line combination cohort demonstrating unprecedented efficacy<\/strong>: an <strong>81.3% objective response rate (ORR)<\/strong> and <strong>97.9% disease control rate (DCR)<\/strong> among 48 efficacy-evaluable patients. The regimen also showed <strong>74.6% 6-month progression-free survival (PFS)<\/strong> and <strong>53.7% 12-month PFS rates<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-clinical-trial-results\" class=\"wp-block-heading\">Clinical Trial Results<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Result<\/th><\/tr><\/thead><tbody><tr><td><strong>Patient Population<\/strong><\/td><td>First-line KRAS G12C-mutant NSCLC (52 patients enrolled)<\/td><\/tr><tr><td><strong>Regimen<\/strong><\/td><td>Elisrasib 600 mg once daily + pembrolizumab 200 mg Q3W<\/td><\/tr><tr><td><strong>Efficacy-Evaluable Patients<\/strong><\/td><td>48<\/td><\/tr><tr><td><strong>Objective Response Rate (ORR)<\/strong><\/td><td><strong>81.3%<\/strong><\/td><\/tr><tr><td><strong>Disease Control Rate (DCR)<\/strong><\/td><td><strong>97.9%<\/strong><\/td><\/tr><tr><td><strong>6-Month PFS Rate<\/strong><\/td><td><strong>74.6%<\/strong><\/td><\/tr><tr><td><strong>12-Month PFS Rate<\/strong><\/td><td><strong>53.7%<\/strong><\/td><\/tr><tr><td><strong>Safety Profile<\/strong><\/td><td>Consistent with known profiles of individual agents<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule<\/strong>: <strong>Elisrasib (D3S-001)<\/strong> \u2013 <strong>next-generation KRAS G12C inhibitor<\/strong><\/li>\n\n\n\n<li><strong>Target<\/strong>: KRAS G12C mutation, present in approximately <strong>13% of NSCLC cases<\/strong><\/li>\n\n\n\n<li><strong>Combination Strategy<\/strong>: Synergistic approach combining <strong>KRAS pathway inhibition<\/strong> with <strong>PD-1 immune checkpoint blockade<\/strong><\/li>\n\n\n\n<li><strong>Dosing<\/strong>: Oral administration (600 mg once daily) with convenient weekly pembrolizumab dosing<\/li>\n\n\n\n<li><strong>Development Stage<\/strong>: Phase I\/II clinical trial with focus on first-line treatment setting<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-clinical-implications\" class=\"wp-block-heading\">Strategic Clinical Implications<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The ASCO 2026 data positions elisrasib as a potential <strong>practice-changing therapy<\/strong> in first-line KRAS G12C-mutant NSCLC:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Unprecedented ORR<\/strong>: <strong>81.3% response rate<\/strong> significantly exceeds historical benchmarks for first-line NSCLC therapies<\/li>\n\n\n\n<li><strong>High Disease Control<\/strong>: <strong>97.9% DCR<\/strong> indicates near-universal disease stabilization or improvement<\/li>\n\n\n\n<li><strong>Durable Responses<\/strong>: <strong>53.7% 12-month PFS rate<\/strong> suggests meaningful long-term benefit<\/li>\n\n\n\n<li><strong>First-Line Focus<\/strong>: Addresses the largest treatment-na\u00efve patient population with optimal therapeutic window<\/li>\n\n\n\n<li><strong>Combination Rationale<\/strong>: KRAS inhibition may enhance tumor immunogenicity, creating synergy with PD-1 blockade<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">&#8220;This remarkable efficacy data establishes elisrasib plus pembrolizumab as a highly promising first-line treatment option for KRAS G12C-mutant NSCLC,&#8221; said Dr. Li Ming, Chief Executive Officer of D3 Bio. &#8220;The 81% response rate and excellent disease control demonstrate the power of combining targeted therapy with immunotherapy in this molecularly defined patient population.&#8221;<\/p>\n\n\n\n<h2 id=\"h-competitive-landscape-amp-market-opportunity\" class=\"wp-block-heading\">Competitive Landscape &amp; Market Opportunity<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The results position D3 Bio to challenge established players in the KRAS G12C inhibitor space:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Market Context<\/strong>: KRAS G12C represents one of the most common oncogenic drivers in NSCLC with significant unmet need<\/li>\n\n\n\n<li><strong>Competitive Differentiation<\/strong>: First-line data with <strong>81% ORR<\/strong> substantially exceeds historical response rates for single-agent KRAS inhibitors (~40\u201345% in second-line)<\/li>\n\n\n\n<li><strong>Addressable Population<\/strong>: Approximately <strong>15,000\u201320,000 newly diagnosed KRAS G12C-mutant NSCLC patients annually in the U.S.<\/strong><\/li>\n\n\n\n<li><strong>Global Potential<\/strong>: Data supports rapid international regulatory filings and partnership opportunities<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Industry analysts view the <strong>81% ORR in first-line setting<\/strong> as potentially <strong>transformative<\/strong>, with peak annual sales estimates of <strong>$2\u20133 billion<\/strong> if Phase III confirms these results, given the substantial addressable market and premium pricing potential for breakthrough first-line therapies.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development, regulatory pathways, and market opportunities for elisrasib. Actual results may differ due to clinical trial outcomes, regulatory decisions, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>D3 Bio, a China-based biotechnology company, presented updated Phase I\/II clinical data for elisrasib (D3S-001),&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[106,17,1122],"class_list":["post-67004","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-academic-conference","tag-clinical-trial-results","tag-d3-bio"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>D3 Bio&#039;s Next-Gen KRAS G12C Inhibitor Elisrasib Shows 81% Response Rate in First-Line NSCLC at ASCO 2026 - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"D3 Bio, a China-based biotechnology company, presented updated Phase I\/II clinical data for elisrasib (D3S-001), its next-generation KRAS G12C inhibitor, at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The study evaluated elisrasib as monotherapy and in combination with pembrolizumab in patients with KRAS G12C-mutant (G12Cmut) non-small cell lung cancer (NSCLC), with the first-line combination cohort demonstrating unprecedented efficacy: an 81.3% objective response rate (ORR) and 97.9% disease control rate (DCR) among 48 efficacy-evaluable patients. The regimen also showed 74.6% 6-month progression-free survival (PFS) and 53.7% 12-month PFS rates.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=67004\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"D3 Bio&#039;s Next-Gen KRAS G12C Inhibitor Elisrasib Shows 81% Response Rate in First-Line NSCLC at ASCO 2026\" \/>\n<meta property=\"og:description\" content=\"D3 Bio, a China-based biotechnology company, presented updated Phase I\/II clinical data for elisrasib (D3S-001), its next-generation KRAS G12C inhibitor, at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The study evaluated elisrasib as monotherapy and in combination with pembrolizumab in patients with KRAS G12C-mutant (G12Cmut) non-small cell lung cancer (NSCLC), with the first-line combination cohort demonstrating unprecedented efficacy: an 81.3% objective response rate (ORR) and 97.9% disease control rate (DCR) among 48 efficacy-evaluable patients. The regimen also showed 74.6% 6-month progression-free survival (PFS) and 53.7% 12-month PFS rates.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=67004\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-01T12:27:05+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-01T12:27:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67004#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67004\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"D3 Bio&#8217;s Next-Gen KRAS G12C Inhibitor Elisrasib Shows 81% Response Rate in First-Line NSCLC at ASCO 2026\",\"datePublished\":\"2026-06-01T12:27:05+00:00\",\"dateModified\":\"2026-06-01T12:27:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67004\"},\"wordCount\":502,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Academic conference\",\"Clinical trial results\",\"D3 Bio\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67004#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67004\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=67004\",\"name\":\"D3 Bio's Next-Gen KRAS G12C Inhibitor Elisrasib Shows 81% Response Rate in First-Line NSCLC at ASCO 2026 - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-01T12:27:05+00:00\",\"dateModified\":\"2026-06-01T12:27:06+00:00\",\"description\":\"D3 Bio, a China-based biotechnology company, presented updated Phase I\\\/II clinical data for elisrasib (D3S-001), its next-generation KRAS G12C inhibitor, at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The study evaluated elisrasib as monotherapy and in combination with pembrolizumab in patients with KRAS G12C-mutant (G12Cmut) non-small cell lung cancer (NSCLC), with the first-line combination cohort demonstrating unprecedented efficacy: an 81.3% objective response rate (ORR) and 97.9% disease control rate (DCR) among 48 efficacy-evaluable patients. The regimen also showed 74.6% 6-month progression-free survival (PFS) and 53.7% 12-month PFS rates.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67004#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67004\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67004#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"D3 Bio&#8217;s Next-Gen KRAS G12C Inhibitor Elisrasib Shows 81% Response Rate in First-Line NSCLC at ASCO 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"D3 Bio's Next-Gen KRAS G12C Inhibitor Elisrasib Shows 81% Response Rate in First-Line NSCLC at ASCO 2026 - Insight, China&#039;s Pharmaceutical Industry","description":"D3 Bio, a China-based biotechnology company, presented updated Phase I\/II clinical data for elisrasib (D3S-001), its next-generation KRAS G12C inhibitor, at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The study evaluated elisrasib as monotherapy and in combination with pembrolizumab in patients with KRAS G12C-mutant (G12Cmut) non-small cell lung cancer (NSCLC), with the first-line combination cohort demonstrating unprecedented efficacy: an 81.3% objective response rate (ORR) and 97.9% disease control rate (DCR) among 48 efficacy-evaluable patients. The regimen also showed 74.6% 6-month progression-free survival (PFS) and 53.7% 12-month PFS rates.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=67004","og_locale":"en_US","og_type":"article","og_title":"D3 Bio's Next-Gen KRAS G12C Inhibitor Elisrasib Shows 81% Response Rate in First-Line NSCLC at ASCO 2026","og_description":"D3 Bio, a China-based biotechnology company, presented updated Phase I\/II clinical data for elisrasib (D3S-001), its next-generation KRAS G12C inhibitor, at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The study evaluated elisrasib as monotherapy and in combination with pembrolizumab in patients with KRAS G12C-mutant (G12Cmut) non-small cell lung cancer (NSCLC), with the first-line combination cohort demonstrating unprecedented efficacy: an 81.3% objective response rate (ORR) and 97.9% disease control rate (DCR) among 48 efficacy-evaluable patients. The regimen also showed 74.6% 6-month progression-free survival (PFS) and 53.7% 12-month PFS rates.","og_url":"https:\/\/flcube.com\/?p=67004","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-01T12:27:05+00:00","article_modified_time":"2026-06-01T12:27:06+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=67004#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=67004"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"D3 Bio&#8217;s Next-Gen KRAS G12C Inhibitor Elisrasib Shows 81% Response Rate in First-Line NSCLC at ASCO 2026","datePublished":"2026-06-01T12:27:05+00:00","dateModified":"2026-06-01T12:27:06+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=67004"},"wordCount":502,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Academic conference","Clinical trial results","D3 Bio"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=67004#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=67004","url":"https:\/\/flcube.com\/?p=67004","name":"D3 Bio's Next-Gen KRAS G12C Inhibitor Elisrasib Shows 81% Response Rate in First-Line NSCLC at ASCO 2026 - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-01T12:27:05+00:00","dateModified":"2026-06-01T12:27:06+00:00","description":"D3 Bio, a China-based biotechnology company, presented updated Phase I\/II clinical data for elisrasib (D3S-001), its next-generation KRAS G12C inhibitor, at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The study evaluated elisrasib as monotherapy and in combination with pembrolizumab in patients with KRAS G12C-mutant (G12Cmut) non-small cell lung cancer (NSCLC), with the first-line combination cohort demonstrating unprecedented efficacy: an 81.3% objective response rate (ORR) and 97.9% disease control rate (DCR) among 48 efficacy-evaluable patients. The regimen also showed 74.6% 6-month progression-free survival (PFS) and 53.7% 12-month PFS rates.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=67004#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=67004"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=67004#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"D3 Bio&#8217;s Next-Gen KRAS G12C Inhibitor Elisrasib Shows 81% Response Rate in First-Line NSCLC at ASCO 2026"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67004","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=67004"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67004\/revisions"}],"predecessor-version":[{"id":67005,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67004\/revisions\/67005"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=67004"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=67004"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=67004"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}